ArticleDiscover oncology2025
The role of RETN in stomach adenocarcinoma (STAD): insights from pan-cancer analysis of RNA-seq data based on the TCGA database.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the expression and significance of resistin (RETN) in pan-cancer and determine the prospect of RETN as a biomarker for STAD, providing a new diagnostic and therapeutic target for STAD.
methodsBased on the RNA-seq data from the TCGA database, RETN was comprehensively analyzed from the perspective of pan-cancer. Firstly, the expression of RETN, correlation of immune infiltration, diagnostic efficacy and prognostic value in pan-cancer were investigated. Subsequently, the potential value of RETN as a biomarker for STAD was evaluated. Finally, the potential mechanisms of RETN in STAD were explored, including single-cell expression, PPI, functional enrichment analysis, single-gene correlation, gene co-expression analysis, and immune infiltration correlation.
resultsRETN is upregulated in most tumors and is associated with a variety of immune cells. As a potential biomarker, RETN showed good diagnostic efficacy and prognostic value in a variety of tumors. The prediction model based on pathological stage, sex, age and RETN has a good prediction effect on the overall survival of STAD patients. Single-cell expression analysis showed that RETN was mainly expressed by DC cells and mononuclear/macrophage cells in STAD. Subsequently, RETN and related genes were analyzed from the perspective of PPI and functional enrichment, and the results showed that these genes/proteins were mainly involved in regulating hormone secretion and insulin response. Finally, RETN is also closely associated with immune cells in STAD.
conclusionsRETN is a promising biomarker related to the diagnosis and prognosis of STAD, and is expected to become a new diagnostic and therapeutic target for STAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.